سعر سيرتيكان 1 مجم 60 قرص 2022

Certican 1 mg film-coated tablets (everolimus), 60 tablets. Novartis. Prophylaxis of organ rejection in adult transplant recipients (kidney, heart, liver) per international SmPC; Egyptian leaflet not opened.

• Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant, in combination with ciclosporin for microemulsion and corticosteroids (UK Certican SmPC).Population: Adults (kidney or heart transplant)MHRA / electronic Medicines Compendium (eMC)
• Prophylaxis of organ rejection in adult patients receiving a hepatic transplant, in combination with tacrolimus and corticosteroids (UK Certican SmPC).Population: Adults (liver transplant)MHRA / electronic Medicines Compendium (eMC)

• Very common: infections, anaemia, hyperlipidaemia, new-onset diabetes, insomnia, headache, hypertension, cough, constipation, nausea, peripheral oedema, impaired healing (UK Certican SmPC).International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

• Contraindicated in patients with known hypersensitivity to everolimus, sirolimus, or any of the excipients (UK Certican SmPC).International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

• Increased risk of opportunistic infections (including BK nephropathy and JC PML), malignancies (especially skin), wound-healing complications, hyperlipidaemia, proteinuria, interstitial lung disease/non-infectious pneumonitis, and new-onset diabetes; live vaccines should be avoided (UK Certican SmPC).International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

• Strong CYP3A4/P-gp inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir)MajorMay markedly increase everolimus exposure; co-administration not recommended unless benefit outweighs risk; monitor troughs if unavoidable (UK Certican SmPC).MHRA / electronic Medicines Compendium (eMC)
• Strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, St John's wort)MajorMay decrease everolimus exposure; co-administration not recommended unless benefit outweighs risk; monitor troughs (UK Certican SmPC).MHRA / electronic Medicines Compendium (eMC)

• Should not be given to pregnant women unless potential benefit outweighs potential risk to the foetus; women of childbearing potential should use effective contraception during treatment and for up to 8 weeks after stopping (UK Certican SmPC).International label, same formulation · MHRA / electronic Medicines Compendium (eMC)
• Women taking Certican should not breast-feed (unknown if excreted in human milk; animal data show transfer) (UK Certican SmPC).International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

• Everolimus: Forms a complex with FKBP-12 that inhibits mTOR (FRAP), blocking growth-factor-driven T-cell proliferation and arresting cells in G1.